Thyme Care
Thyme Care enhances the cancer journey with expert oncology navigation and care teams, partnering to improve access, outcomes, and costs. They describe themselves as a startup transforming the cancer experience.
Classification
Profile
Funding
Funding details not yet available.
Signals
Enhances the cancer journey through expert oncology navigation and care teams to improve access, outcomes, and costs in a value-based care framework.
Healthcare systems and payers in the DACH region seeking to optimize oncology care pathways and reduce costs.
SaaS/Subscription (B2B contract) with usage-based elements for care delivery
Direct sales (enterprise sales), channel partners
Partners with healthcare providers and payers to deliver oncology navigation services and integrate care teams.
R&D, clinical staff costs, customer acquisition, technology infrastructure
Expert oncology navigation professionals and a dedicated oncology care team focused on transforming the patient experience.
Providing oncology navigation services and managing care teams to improve access and outcomes for cancer patients.
Sales-led (B2B), self-serve (end-user app), community support
Positions itself as a leader in oncology navigation for value-based care, differentiating through expert navigation and integrated care teams.
Addresses challenges in cancer access, suboptimal patient outcomes, and high healthcare costs within the oncology pathway.
- Expand AI-driven triage - Deploy predictive analytics on ePRO data to proactively flag high-risk patients, reducing navigator labor per c
Value Proposition ↔ Revenue Streams - The promise of cost-savings directly fuels PMPM fees and performance bonuses · Key Activities ↔ Cost Structure - 24/7 clinical staffing drives personnel costs; investing in automation (ePRO alerts) can reduce per-patien · Channels ↔ Customer Relationships - The “ThymeCare Connect” hub not only delivers the serv
- Evidence-based outcomes - Multiple peer-reviewed studies (e.g., JCO Oncology Practice 2022) show navigation reduces ER utilization by 15-
No investors recorded yet.